Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03305293 in Advanced Solid Tumors
NCT04182516Phase 1Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Nov 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of itareparib in breast cancer, Epithelial Ovarian Cancer (EOC), prostate cancer (PCa) and 1 more (6 arms), sponsored by Nerviano Medical Sciences. Primary endpoint: Dose Limiting Toxicity. Started Nov 2019; status: terminated.
02
Drugs
itareparib
03
Conditions
breast cancerEpithelial Ovarian Cancer (EOC)prostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04182516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182516.